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Results: C1 = 109 patients (84 with breast cancer, 13 H&N, 
12 pelvis), C2= 104 (87B, 12H&N, 5P). In C1 27% used a cream 
and in C2 96% used a cream (p<0.001). In C2 88/104 complied 
with policy using the prescribed betamethasone.  
Compared to C1, for C2 the mean score was lower for itch 
(1.3 (0.8-1.8) v 2.8 (2.2-3.4) p<0.001) and discomfort (2.2 
(1.7-2.7) v 3.1 (2.6-3.7) (p=0.021), and when betamethasone 
was used (comparing the 88 from C2 with 125 from C1 or C2) 
the mean score was lower for itch (0.9 (0.5-1.4) v 2.9 (2.3-
3.4) p<0.001), discomfort (2.0 (1.4-2.5) v 3.2(2.6-3.7) 
p<0.003), and for pain (1.4 (0.9-1.9) v 2.2 (1.7-2.7) p=0.03).  
With the use of betamethasone, the frequency of a score of 
>5 was lower for redness (15% with v 34% without) p=0.002), 
itch (7% v 25%, p =0.001), discomfort (9% v 22%, p=0.015), but 
not for pain (9% v 14%, p=0.29). However, sleep disturbance 
was less common (7% v 21%, p=0.006), as was the use of 
analgesia (7% v 19%, p=0.015). 
 
Conclusion: The introduction of routine use of prophylactic 
betamethasone cream for patients with a high risk of 
radiation skin reaction resulted in a significant reduction in 
redness, itch, discomfort, sleep disturbance, and on use of 
analgesia 
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Purpose or Objective: The use of complementary and 
alternative medicine (CAM) continuously gains importance, 
even though objective data are mostly missing – also in 
radiation oncology. However, in previous trials methods such 
as acupuncture showed significant advantages compared to 
standard therapies. Hence, the aim of this study is to 
evaluate the most frequently used methods, their 
significance and potential effect during radiotherapy (RT), as 
well as the general acceptance amongst cancer patients. 
 
Material and Methods: A detailed questionnaire was 
developed consisting of 18 questions based on the categorical 
classification released by the National Centre for 
Complementary and Alternative Medicine (NCCAM). From 
January to September 2015, the survey was conducted with 
all patients undergoing RT at the department of Radiation 
Oncology, Technische Universität München (TUM), Klinikum 
rechts der Isar, Munich. Participation was voluntary and 
pseudonymous. 
 
Results: Of 571 patients, 289 answered the questionnaire 
(50.6%), with 44.6% females and 38.4% males participating in 
the study, and a mean age of 60 years. Of these, 66.1% 
(191/289) received RT only, 20.4% (59/289) had a combined 
radio-chemotherapy (RCT). Of all participants, 25.9% 
(75/289) used CAM parallel to RT. Before RT, a total of 40.8% 
(118/289) had already used complementary medicine. The 
current most frequently applied methods were vitamins, 
dietary supplements, homeopathy and physical therapy, 
whereas in the past before RT also acupuncture and 
osteopathy had been regularly used. The majority (72.6%, 
210/289) declined the use of any complementary treatment. 
Of these 210 patients, 73.3% (154/210) stated that CAM 
treatment was not offered to them. Only 20.4% (59/289) of 
all participants had discussed adding complementary 
treatments to their current therapy with their consulting 
physician. The most common reasons for CAM use were 
intended by the patients to improve the immune system 
(47%, 136/289), to reduce side effects (43.2%, 125/289), and 
to not miss an opportunity (37.3%, 108/289). Assuming their 
health insurance would not compensate the costs for CAM 
during RT, 52.5% (152/289) of the patients would pay for 
their treatment. A treatment integrated in the individual 
therapy concept, such as regular acupuncture, would be used 
by 62.9% (182/289) of RT patients. In order to gain more 
information about the changes in attitude towards 
complementary medicine, we also handed out the 
questionnaire a second time after RT during the first follow-
up visit (n=10). This is an ongoing part of the evaluation. 
However, it becomes apparent that in retrospect the use of 
CAM increased.  
 
Conclusion: In comparison to other studies, usage of CAM 
parallel to RT is considered to be low. The acceptance 
amongst patients is present, however more information, in 
terms of personal consultations with physicians, brochures or 
online information, could encourage a holistic therapy. 
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Purpose or Objective: On the basis of successful 
intralesional steroid injection for dermatologic scars 
treatment such as keloids and burn scars, we planned to 
evaluate intralesional triamcinolone acetonide injection in 
treatment of RIF as there is no data available for its use for 
this indication 
 
Material and Methods: 30 patients with RIF of different sites 
(19 cases breast, 4 cases neck, 3 back, 2 face and 2 lower 
limbs) at least 6 months after end of radiation were included 
in our study. They were treated by intralesional 
Triamcinolone acetonide injection. Injections were carried 
out by dermojet at 1 cm interval. Injections were repeated 
every 2 weeks for 3months. Assessment was done according 
to RTOG grading before treatment and repeated during and 3 
months after end of treatment. 
 
Results: We documented over all response rates of 80%, 
marked and complete improvement of RIF 43.33%, 30% 
showed one grade improvement, 6.67% had two grades 
improvement, while 20% of patients didn't respond (P-value 
<0.001). Pain score was significantly improved (p value 
<0.001), 44% of the included patients had complete 
improvement of pain, 36% had mild residual pain and 20% of 
patients expressed moderate residual pain. No significant 
adverse events were observed. The results were significantly 
better with younger age group (P-value=0.021), smaller BMI 
(p-value=0.007), patients who received lower radiation doses 
(P value =0.03), smaller number of radiotherapy treatment 
sessions (P-value=0.05), smaller radiation field sizes (P 
value=0.001), and patients with shorter duration of RIF (P 
value <0.001). 
 
Conclusion: Intralesional triamcinolone acetonide injection 
can be considered as an effective in treatment of RIF. It can 
be considered as a promising effective, safe, less costly 
therapeutic option in treatment of RIF. To the best of our 
knowledge, no previous data are available about the use of 
intralesional injection of triamcinolone acetonide for 
treatment of RIF. 
Key words: Radiation, fibrosis, intralesional.  
 
EP-1471  
The effect of radiotherapy on Ledderhose disease 
J.G.H. Van Nes
1University Medical Centre Groningen, Radiotherapy, 
Groningen, The Netherlands 
1, J.A. Langendijk1, R.J.H.M. Steenbakkers1 
 
Purpose or Objective: The only treatment option for 
Ledderhose disease seems radiotherapy as surgery is 
associated with a high chance of recurrence and morbidity. 
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Therefore, we investigated the effect of radiotherapy on 
Ledderhose disease. 
 
Material and Methods: Between 2008 and 2014, 37 patients 
(56 feet) with Ledderhose disease were treated with 
radiotherapy at our department (figure 1). Radiation 
treatment consisted of 30 Gy given in 10 fractions (orthovolt 
200 kV or electrons 6-10 MeV). After the first 5 fractions, a 8-
10 week split was included. After this split, the remaining 5 
fractions were given. Progressive disease (PD) was defined as 
progression of complaints. Stable disease (SD) was defined as 
no improvement or progression of complaints. Partial 
response (PR) was defined as improvement or no complaints, 
but still nodules were present. Complete response (CR)was 
defined as no complaints and no nodules present. 
 
Results: All patients completed the planned treatment. The 
mean follow-up time was 25 months (range 3 to 46 months). 
Mean age of patients was 53 years, 46% were men, 54% were 
women. In 51% of patients (n=19), both feet were affected. 
After the radiotherapy, a minority of the patients complained 
of rash or dry skin, which resolved spontaneously. Of the 56 
feet treated, 5% had PD, 23% had SD, 64% had PR and 7% had 
CR. No radiation induced malignancies were seen. Of the two 
patients with PD, one patient had previous surgery for 
Ledderhose disease and the other patient had PD disease 
after an initial PR. 
 
 
Conclusion: Radiotherapy is an effective treatment for 
Ledderhose disease. However, the National Health Care 
Institute of the Netherlands does not support radiotherapy 
for Ledderhose disease as no randomized controlled trail 
have investigated the efficacy of radiotherapy. Therefore, we 
will present a double blind randomized multicentre phase 
three study to confirm the current results prospectively. 
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Purpose or Objective: Nowadays stereotactic body 
radiotherapy (SBRT) is considered a safe and effective 
approach for several sites of metastatic disease. So far, few 
published data exist on local control rates of radiotherapy in 
the context of isolated or limited lymph node metastases. We 
analyzed the dosimetric and clinical results of 
oligometastatic patients treated with SBRT for isolated lymph 
node metastases in abdomen and/or pelvis. 
 
Material and Methods: In the analysis we included patients 
with a maximum of 3 lymph node sites of disease with 
diameter less than 5 cm, located in the abdomen or pelvis. 
Radiotherapy was administered with Volumetric Modulated 
Arc Therapy Rapid-Arc (VMAT-RA) and flattening filter-free 
(FFF) beams; prescribed dose was 45 Gy in 6 fractions of 7.5 
Gy each. We analyzed dosimetric data and correlated them 
with acute toxicity (CTCAE 3.0), local and distant control of 
disease, progression free survival and overall survival. 
 
Results: From January 2006 to May 2015, we treated 97 
patients with lymph node metastases, of which 26 were lost 
at follow-up. We analyzed then 71 patients with a total of 79 
treated lesions, with a mean follow-up of 1.44 years (range 
0.14 – 6.21 years). At revaluation, complete response was 
achieved in 39 (49.3%) lesions and partial response in 28 
(35.4%) lesions. Stable disease was demonstrated in 10 
(12.6%) cases while only 2 (2.5%) lesions showed progression 
of disease. The overall clinical benefit rate was 97.5% (77/79 
lesions). Acute toxicity was mild: 10 (14%) patients reported 
G1 toxicity (notably nausea and fatigue); 2 (2.8%) patients 
reported G2 toxicity (nausea and diarrhea). No Grade 3 and 4 
toxicities were reported. In-field progression of disease 
during follow-up was demonstrated in 18 sites (22.7%) with a 
median time of 10.7 months. Out-field lymph node 
progression was demonstrated in 22 (27.8%) cases while 
distant metastases occurred in 25 (31.6%) cases. Local control 
rate and overall survival rate at 1 year were 83% and 93%, 
respectively. 
 
Conclusion: In consideration of our dosimetric and clinical 
results, SBRT with VMAT-RA and FFF beams can be considered 
a safe and effective approach in oligometastatic patients 
with abdomino-pelvic isolated lymph node metastases. 
Although this can be considered an initial experience, these 
results may be potentially significant for preserving quality of 
life of patients and delaying further systemic treatments. 
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Purpose or Objective: The purpose of this study was to 
evaluate the efficacy and feasibility of carbon ion 
